A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).

Yasuyuki IkezawaHajime AsahinaSatoshi OizumiMasahiro WatanabeKei TakamuraYasutaka KawaiNoriyuki YamadaToshiyuki HaradaIchiro KinoshitaYuka FujitaEisaku MiyauchiTakahiro OgiToraji AmanoMegumi FurutaJun Sakakibara-KonishiHiroshi NishiharaHirotoshi Dosaka-AkitaHiroshi IsobeMasaharu Nishimuranull null

Published in: Cancer chemotherapy and pharmacology (2017)

UMIN000005308.

Keyphrases

wild type
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
small cell lung cancer
open label
placebo controlled
clinical trial